Median PFS was @ months ( @ % CI @-not reached ) for the women treated with cediranib plus olaparib compared with @ months ( @ % CI @-@ ) for those treated with olaparib monotherapy ( hazard ratio @ , @ % CI @-@ ; p = @ ) .